Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes

[1]  C. Dai,et al.  Understanding H7N9 avian flu , 2013, BMJ.

[2]  F. Kostolanský,et al.  HA2 glycopolypeptide of influenza A virus and antiviral immunity. , 2013, Acta virologica.

[3]  F. Kostolanský,et al.  Epitope specificity of anti‐HA2 antibodies induced in humans during influenza infection , 2012, Influenza and other respiratory viruses.

[4]  Xuguang Li,et al.  Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge , 2012, Human vaccines & immunotherapeutics.

[5]  G. Domselaar,et al.  Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins and their Biological Relevance , 2011 .

[6]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[7]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[8]  Xuguang Li,et al.  The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. , 2011, Toxicology and applied pharmacology.

[9]  S. Gómez-Puerta,et al.  Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens. , 2011, Comparative immunology, microbiology and infectious diseases.

[10]  D. Ho,et al.  CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells , 2011, Journal of acquired immune deficiency syndromes.

[11]  G. Van Domselaar,et al.  Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. , 2010, Biochemical and biophysical research communications.

[12]  D. Tyrrell,et al.  Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. , 2010, Vaccine.

[13]  H. Nguyen,et al.  CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. , 2010, Human gene therapy.

[14]  Xinglong Wang,et al.  CD40 ligand expressed in adenovirus can improve the immunogenicity of the GP3 and GP5 of porcine reproductive and respiratory syndrome virus in swine. , 2010, Vaccine.

[15]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[16]  D. Curiel,et al.  Selective Transduction of Dendritic Cells in Human Lymph Nodes and Superior Induction of High-avidity Melanoma-reactive Cytotoxic T Cells by a CD40-targeted Adenovirus , 2010, Journal of immunotherapy.

[17]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[18]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[19]  M. Esteban,et al.  Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. , 2009, Vaccine.

[20]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[21]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[22]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[23]  P. Verardi,et al.  Incorporation of CD40 Ligand into the Envelope of Pseudotyped Single-Cycle Simian Immunodeficiency Viruses Enhances Immunogenicity , 2008, Journal of Virology.

[24]  G. Van Domselaar,et al.  Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. , 2008, Vaccine.

[25]  T. Randall,et al.  A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.

[26]  M. Ostrowski,et al.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. , 2008, Vaccine.

[27]  D. Curiel,et al.  Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells , 2007, Gene Therapy.

[28]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[29]  S. Epstein.  Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. , 2006, The Journal of infectious diseases.

[30]  J. Shellito,et al.  CD4+ T cell-independent DNA vaccination against opportunistic infections. , 2005, The Journal of clinical investigation.

[31]  L. Nadler,et al.  Correspondence re R. Lapointe et al., CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells. Cancer Res 2003;63:2836–43. , 2004, Cancer Research.

[32]  H. Hauser,et al.  Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines , 2004, Gene Therapy.

[33]  D. Curiel,et al.  Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[35]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Hwu,et al.  CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. , 2003, Cancer research.

[37]  G. Bishop,et al.  The CD40-CD154 interaction in B cell-T cell liaisons. , 2003, Cytokine & growth factor reviews.

[38]  E. Falk,et al.  Experiment of nature , 2002 .

[39]  W. Gerhard.  The role of the antibody response in influenza virus infection. , 2001, Current topics in microbiology and immunology.

[40]  K Cameron,et al.  Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Michael P. Brown,et al.  CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse , 2000, The Journal of Immunology.

[42]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[43]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[44]  Y. Guan,et al.  Avian-to-human transmission of H 9 N 2 subtype influenza A viruses : Relationship between H 9 N 2 and H 5 N 1 human isolates , 2000 .

[45]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[46]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[47]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[48]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[49]  R. Zinkernagel,et al.  CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions , 1996, The Journal of experimental medicine.

[50]  W. Weissenhorn,et al.  A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Skehel,et al.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. , 1987, Annual review of biochemistry.

[52]  R. Webster,et al.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies , 1981, Nature.

[53]  J. M. Grant.  'An experiment in nature'. , 1978, Archives of dermatology.

[54]  H. Frost,et al.  The American Journal of Hygiene , 1920, Science.